BD Announces U.S. Commercial Launch of Liverty TIPS Stent Graft for Portal Hypertension Care

Global medical technology company BD has announced the U.S. commercial launch of the BD Liverty TIPS Stent Graft, a system designed to advance portal hypertension care by offering physicians greater flexibility to tailor treatments to individual patient needs. Reported details indicate that the product enters the U.S. market following prior clinical and physician experience in Europe, alongside interim results from the ARCH clinical study.

Portal hypertension can cause serious complications, including internal bleeding and fluid accumulation in the abdomen. The Liverty TIPS Stent Graft aims to help manage these conditions through customizable features.

Key Features of the Liverty TIPS Stent Graft

• Expandable diameter design ranging from 6 to 10 mm to address patient-specific hemodynamics.
• Covered stent lengths from 4 to 10 cm, reported as the longest commercially available option to support varied anatomies.
• A fully sheathed, tri-axial delivery system intended for deployment accuracy, control, and ease of use.
• Radiopaque markers and a marker band designed to assist with visualization and accurate placement during fluoroscopy.
• A delivery system enabling sheath-less tracking through the liver parenchyma.

Practical Implications and Verification

The introduction of this device expands BD's interventional portfolio. Clinicians and interested parties can review official announcements and verify product details directly through BD's corporate communications or by visiting bd.com/Liverty. As with all medical device deployments, practitioners are encouraged to consult official prescribing information and clinical trial data for complete safety and usage guidelines.